Development
e-therapeutics plc
ETXPF
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 101.30K | 97.70K | 108.50K | 103.80K | 180.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 101.30K | 97.70K | 108.50K | 103.80K | 180.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 101.30K | 97.70K | 108.50K | 103.80K | 180.70K |
| SG&A Expenses | 1.14M | 1.10M | 1.06M | 1.02M | 1.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.52M | 4.36M | 3.54M | 3.38M | 2.97M |
| Operating Income | -4.41M | -4.26M | -3.43M | -3.28M | -2.79M |
| Income Before Tax | -4.20M | -4.05M | -3.17M | -3.03M | -2.77M |
| Income Tax Expenses | -656.70K | -633.50K | -475.70K | -454.90K | -434.30K |
| Earnings from Continuing Operations | -3.54M | -3.42M | -2.69M | -2.57M | -2.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.54M | -3.42M | -2.69M | -2.57M | -2.33M |
| EBIT | -4.41M | -4.26M | -3.43M | -3.28M | -2.79M |
| EBITDA | -4.24M | -4.09M | -3.41M | -3.22M | -2.64M |
| EPS Basic | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 576.70M | 576.70M | 559.56M | 559.56M | 515.14M |
| Average Diluted Shares Outstanding | 576.70M | 576.70M | 559.56M | 559.56M | 515.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |